Opening book details…
About this book
Application of C–H Functionalization in the Development of a Concise and Convergent Route to the Phosphatidylinositol-3-kinase Delta Inhibitor Nemiralisib by Robert N. Bream, Hugh Clark, Dean Edney, Antal Harsanyi, John Hayler, Alan Ironmonger, Nadine Mc Cleary, Natalie Phillips, Catherine Priestley, Alastair Roberts, Philip Rushworth, Peter Szeto, Michael R. Webb & Katherine Wheelhouse is a book available to read on EtoBox.
- Author
- Robert N. Bream, Hugh Clark, Dean Edney, Antal Harsanyi, John Hayler, Alan Ironmonger, Nadine Mc Cleary, Natalie Phillips, Catherine Priestley, Alastair Roberts, Philip Rushworth, Peter Szeto, Michael R. Webb & Katherine Wheelhouse
- Published
- 2021
- Language
- EN
More by Robert N. Bream, Hugh Clark, Dean Edney, Antal Harsanyi, John Hayler, Alan Ironmonger, Nadine Mc Cleary, Natalie Phillips, Catherine Priestley, Alastair Roberts, Philip Rushworth, Peter Szeto, Michael R. Webb & Katherine Wheelhouse
Similar books
- Development of a Nitrene-Type Rearrangement for the Commercial Route of the JAK1 Inhibitor Abrocitinib — Christina G. Connor, Jacob C. DeForest, Phil Dietrich, Nga M. Do, Kevin M. Doyle, Shane Eisenbeis, Elizabeth Greenberg, Sarah H. Griffin, Brian P. Jones, Kris N. Jones, Michael Karmilowicz, Rajesh Kumar, Chad A. Lewis, Emma L. McInturff, J. Christopher... (2021)
- Development of a Practical and Scalable Synthetic Route for the Adenosine Monophosphate-Activated Protein Kinase Activator, ASP4132 — Takayoshi Tajima, Hiroaki Hoshii & Yoshinori Kohmura (2021)
- Optimization and Development of a Scalable Palladium-Catalyzed C–H Activation Process for the Geometry-Selective Preparation of Kilograms of YLF466D, a Potent AMP-Activated Protein Kinase Activator — Jianpeng Yin, Desheng Zhan, Hui Ma, Huanan Liu, Lifang Yu, Yangming Zhang & Fajun Nan (2021)
- Development of a Synthesis Process for a Novel HCV NS5A Inhibitor, Emitasvir — Hongming Xie, Haiwang Liu, Yingjun Zhang, Enhuo Huang, Yahui Feng, Xuwen Xiang, Qinghong Fang, Zhihong Peng, Wanrong Dong & Delie An (2021)
- Development of the Enabling Route for a Novel HCV NS3/4A Inhibitor, Furaprevir — Weihong Zhang, Shixi Li, Haiwang Liu, Yingjun Zhang, Hongpeng Xie, Dahua Peng, Hongtao Peng, Zijian Ou, Zhihong Peng, Wanrong Dong & Delie An (2022)
- Development of a Commercial Manufacturing Route to 2-Fluoroadenine, The Key Unnatural Nucleobase of Islatravir — Cynthia M. Hong, Yingju Xu, John Y. L. Chung, Danielle M. Schultz, Mark Weisel, Richard J. Varsolona, Yong-Li Zhong, Akasha K. Purohit, Cyndi Q. He, Donald R. Gauthier, Guy R. Humphrey, Kevin M. Maloney, François Lévesque, Zhixun Wang, Aaron M.... (2021)